Impact Partnership Wealth LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD

Impact Partnership Wealth LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 66.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,138 shares of the biopharmaceutical company’s stock after acquiring an additional 5,232 shares during the quarter. Impact Partnership Wealth LLC’s holdings in Gilead Sciences were worth $1,457,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $25,000. Activest Wealth Management lifted its stake in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the second quarter valued at approximately $27,000. Finally, Colonial Trust Advisors grew its holdings in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Rothschild & Co Redburn boosted their price objective on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a report on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $122.61.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $118.50 on Thursday. The company has a fifty day moving average price of $115.51 and a 200 day moving average price of $111.43. The firm has a market cap of $147.04 billion, a PE ratio of 23.61, a PEG ratio of 0.81 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the transaction, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 71,500 shares of company stock valued at $8,336,040 over the last 90 days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.